Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Bioventus Inc (BVS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: BVS (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12.75
1 Year Target Price $12.75
| 2 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 79.35% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 457.54M USD | Price to earnings Ratio 228 | 1Y Target Price 12.75 |
Price to earnings Ratio 228 | 1Y Target Price 12.75 | ||
Volume (30-day avg) 3 | Beta 0.84 | 52 Weeks Range 5.81 - 14.38 | Updated Date 09/17/2025 |
52 Weeks Range 5.81 - 14.38 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.03 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 0.33% | Operating Margin (TTM) 12.45% |
Management Effectiveness
Return on Assets (TTM) 3.64% | Return on Equity (TTM) 1.39% |
Valuation
Trailing PE 228 | Forward PE 7.77 | Enterprise Value 765871352 | Price to Sales(TTM) 0.81 |
Enterprise Value 765871352 | Price to Sales(TTM) 0.81 | ||
Enterprise Value to Revenue 1.36 | Enterprise Value to EBITDA 8.81 | Shares Outstanding 66892300 | Shares Floating 33720410 |
Shares Outstanding 66892300 | Shares Floating 33720410 | ||
Percent Insiders 11.77 | Percent Institutions 73.5 |
Upturn AI SWOT
Bioventus Inc
Company Overview
History and Background
Bioventus Inc. was founded in 2012 as a spin-off from Smith & Nephew's Biologics division. It focuses on developing and marketing orthobiologic solutions. Key milestones include product launches, acquisitions, and its IPO in 2021.
Core Business Areas
- Active Healing Therapies: This segment focuses on products that promote bone and tissue healing, including bone graft substitutes and ultrasound bone healing systems.
- Pain Relief: This segment includes products designed to relieve pain associated with osteoarthritis and other musculoskeletal conditions, such as viscosupplementation and bracing solutions.
Leadership and Structure
The leadership team consists of the CEO, CFO, and other key executives. The organizational structure is based on functional departments and business units aligned with core business areas.
Top Products and Market Share
Key Offerings
- DUROLANE: DUROLANE is a single-injection hyaluronic acid product used for osteoarthritis pain relief. Competitors include Sanofi (SYNVISC), Seikagaku (GEL-ONE), and Zimmer Biomet (ORTHOVISC). While specific market share for DUROLANE is hard to pinpoint, it's a key player in the viscosupplementation market which is highly competitive.
- EXOGEN: EXOGEN is a non-invasive ultrasound device used to accelerate bone fracture healing. Competitors include Orthofix (Physio-Stim) and DJO Global (bone growth stimulators). EXOGEN holds a significant market share in the ultrasound bone healing systems market, but specific numbers are proprietary. The market share has been impacted by changes in reimbursement policies.
Market Dynamics
Industry Overview
The orthobiologics market is growing, driven by an aging population, increasing prevalence of osteoarthritis and sports injuries, and technological advancements in regenerative medicine.
Positioning
Bioventus is positioned as a leader in orthobiologics, focusing on active healing therapies and pain relief solutions. Its competitive advantages include a diversified product portfolio, established distribution network, and strong brand recognition in specific product categories.
Total Addressable Market (TAM)
The global orthobiologics market is estimated to be in the billions of dollars annually, with projections for continued growth. Bioventus is well-positioned to capture a significant share of this TAM through its existing product portfolio and pipeline of innovative solutions.
Upturn SWOT Analysis
Strengths
- Established brand name in specific orthobiologic segments
- Diversified product portfolio
- Strong distribution network
- Focus on innovation and product development
Weaknesses
- High reliance on reimbursement policies
- Exposure to intense competition
- Potential for product liability claims
- Fluctuations in financial performance
Opportunities
- Expansion into emerging markets
- Development of new orthobiologic therapies
- Acquisition of complementary businesses
- Increased adoption of minimally invasive procedures
Threats
- Changes in reimbursement policies
- Increased competition from larger medical device companies
- Product recalls or safety concerns
- Economic downturns
Competitors and Market Share
Key Competitors
- SNY
- ZBH
- ORTH
Competitive Landscape
Bioventus faces competition from larger medical device companies with greater financial resources. Its advantages include a focus on specific orthobiologic segments and a reputation for innovation. Disadvantages are lower R&D budget than larger competitors and dependence on reimbursement policies.
Major Acquisitions
Misonix, Inc.
- Year: 2021
- Acquisition Price (USD millions): 518
- Strategic Rationale: Expanded Bioventus' offerings in the ultrasonic medical device market and diversified its product portfolio.
Growth Trajectory and Initiatives
Historical Growth: Need financial data to fill this. Replace below 'Numerical Data Required' when information is found.
Future Projections: Need financial data to fill this. Replace below 'Numerical Data Required' when information is found.
Recent Initiatives: Recent initiatives include strategic acquisitions, product launches, and expansion of its sales force.
Summary
Bioventus is a key player in the orthobiologics market, with a diversified product portfolio and a focus on innovation. While it faces competition from larger companies and is sensitive to reimbursement changes, strategic acquisitions and growth initiatives support its long-term prospects. The company needs to focus on reducing cost of goods sold and gaining efficiencies from scale. It should monitor reimbursement trends to ensure adequate product coverage and pricing.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share estimates are approximate and may vary. Financial data should be verified with official company filings.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bioventus Inc
Exchange NASDAQ | Headquaters Durham, NC, United States | ||
IPO Launch date 2021-02-11 | President, CEO & Director Mr. Robert E. Claypoole | ||
Sector Healthcare | Industry Medical Devices | Full time employees 950 | Website https://www.bioventus.com |
Full time employees 950 | Website https://www.bioventus.com | ||
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise of various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides nexus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system; and Talisman pulse generator and receiver for peripheral nerve stimulation. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.